Skip to main content Back to Top
Advertisement

12/7/2021

Leucovorin Calcium Injection

Products Affected - Description

    • Leucovorin Calcium injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 1 count, NDC 63323-0631-10
    • Leucovorin Calcium injection, Fresenius Kabi, 10 mg/mL, 50 mL vial, 1 count, NDC 63323-0631-50
    • Leucovorin Calcium lyophilized powder for solution for injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0711-00
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 100 mg, vial, 1 count, NDC 00143-9554-01
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 50 mg, vial, 1 count, NDC 00143-9555-01
    • Leucovorin Calcium lyophilized powder for solution for injection, Hikma, 350 mg, vial, 1 count, NDC 00143-9552-01
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional, 200 mg, vial, 1 count, NDC 67457-0529-20
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional, 350 mg, vial, 1 count, NDC 67457-0530-35
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 350 mg, vial, 1 count, NDC 25021-0816-30
    • Leucovorin Calcium lyophilized powder for solution for injection, Sagent, 50 mg, vial, 10 count, NDC 25021-0813-10
    • Leucovorin Calcium lyophilized powder for solution for injection, Teva, 100 mg, vial, 1 count, NDC 00703-5140-01
    • Leucovorin Calcium lyophilized powder for solution for injection, Teva, 350 mg, vial, 1 count, NDC 00703-5145-01

Reason for the Shortage

    • Fresenius Kabi has leucovorin on shortage due to manufacturing delays and increased demand.
    • Hikma has leucovorin on shortage due to increased demand.
    • Mylan Institutional has leucovorin on shortage due to increased demand.
    • Sagent has leucovorin on shortage due to manufacturing delays.
    • Teva has leucovorin on shortage due to increased demand.

Available Products

    • Leucovorin Calcium lyophilized powder for solution for injection, Fresenius Kabi, 200 mg, vial, 1 count, NDC 63323-0710-50
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 200 mg, vial, 1 count, NDC 00143-9553-01
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional, 50 mg, vial, 1 count, NDC 67457-0528-10
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 100 mg, vial, 10 count, NDC 25021-0814-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 200 mg, vial, 1 count, NDC 25021-0815-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 500 mg, vial, 1 count, NDC 25021-0828-50

Estimated Resupply Dates

    • Fresenius Kabi has leucovorin 500 mg vials on back order and the company estimates a release date of late-December 2021. The 10 mg/mL 10 mL and 50 mL vials are on back order and the company estimates a release date of mid-January 2022.
    • Hikma has 50 mg vials on back order and the company estimates a release date of late-January to early-February 2022. The 350 mg vial are on allocation. There are short-dated 100 mg vials available with an expiration date of March 2022.
    • Mylan Institutional has leucovorin 200 mg and 350 mg vials on back order and the company estimates a release date of late-December 2021 for the 200 mg vials and early-December 2021 for the 350 mg vials.
    • Sagent has leucovorin 50 mg vials on back order and the company estimates a release date of December 2021. The 350 mg vials are available on limited allocation.
    • Teva has leucovorin 100 mg and 350 mg vials on back order and the company cannot estimate a release date.

Updated

Updated December 7, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 6, 2010 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.